Topical Drug Delivery Market worth $317.8 billion by 2027 - Leading Key Players are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada)

According to the new market research report "Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027", published by MarketsandMarkets™, is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%.

Browse in-depth TOC on "Topical Drug Delivery Market"
234 - Tables
50 - Figures
307 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124871717&utm_source=openpr&utm_medium=referral

The high prevalence of skin diseases, increasing geriatric population, and increase in self medications as a popular practice in dermatology are some of the key factors driving the market for topical drug delivery.

The pandemic has given momentum to the topical drug delivery market worldwide. It is estimated that dermatological diseases, respiratory infections, diabetes, cancer, and neurological complications have surged during the forecast period. During the COVID-19 pandemic surge, several clinical studies were carried out to use topical treatment in COVID-19. For example, researchers at Mansoura University carried out trials to explore the feasibility of combined topical corticosteroid and topical cyclosporine-A for COVID-19 patients suffering from acute keratoconjunctivitis. Post clinical trial, it was observed that symptoms such as eye itching, foreign body sensation, tearing, redness in the eye, and eyelid swelling were improved, and the presence of superficial punctate keratitis (SPK) was reduced. In 2020, Advanced Penetration Technology, LLC, a London-based research lab, analyzed the impact of topical antiviral medicine ATP T3X on the COVID-19 virus. It states that it is a highly effective formulation that neutralizes viral infectivity within seconds. These clinical trials and new FDA-approved topical medications showed that topical drugs effectively reduce the severity of symptoms caused by COVID-19 infection; it increases the demand for topical drugs during the COVID-19 pandemic and can result in the growth of the market.

The semi-solid formulations segment accounted for the largest share of the topical drug delivery market, by product in 2021

Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The large share of the semi-solid formulations segment is attributed to them can be attributed to easy application, limited side effects that improve patient adherence, and the ability to topically deliver a wide variety of drug molecules compared to other formulations.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=124871717&utm_source=openpr&utm_medium=referral

The dermal drug delivery segment accounted for the largest share of the topical drug delivery market in 2021

Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to the several advantages associated with the use of dermal drug delivery, such as the ease of use and increased patient compliance for long-term treatment in cases such as chronic pain or skin disorders. Dermal drugs also have fewer regulatory requirements than ophthalmic products, which leads to more accessible product launches and adoption. This in turn, is expected to enhance the segment market growth.

The home care settings segment accounted for the largest share of the topical drug delivery market in 2021

Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. Topical drug delivery systems are increasingly gaining prominence, not just as an alternative route of drug delivery but also as point-of-care devices in-home care settings. This is mainly attributed to improving patient acceptability of home care due to growing awareness and patient comfort.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=124871717&utm_source=openpr&utm_medium=referral

North America accounted for the largest share of the topical drug delivery market in 2021

In 2021, North America accounted for the largest share the topical drug delivery market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. Market growth in this region is characterized by the availability of favorable reimbursement options, increasing awareness about novel pharmaceutical drug delivery technologies, the implementation of favorable government initiatives, growing affordability and per capita healthcare expenditure, the presence of a large number of global pharmaceutical giants.

The prominent players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.